Advisory Alpha’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.46M | Buy |
9,774
+1,514
| +18% | +$326K | 0.06% | 122 |
|
|
2026
Q1 | $1.8M | Buy |
8,260
+805
| +11% | +$179K | 0.05% | 132 |
|
|
2025
Q4 | $1.7M | Buy |
7,455
+444
| +6% | +$101K | 0.05% | 135 |
|
|
2025
Q3 | $1.66M | Buy |
7,011
+1,280
| +22% | +$261K | 0.05% | 130 |
|
|
2025
Q2 | $1.06M | Buy |
5,731
+701
| +14% | +$130K | 0.03% | 160 |
|
|
2025
Q1 | $1.05M | Buy |
5,030
+683
| +16% | +$133K | 0.04% | 155 |
|
|
2024
Q4 | $773K | Buy |
4,347
+154
| +4% | +$28.3K | 0.03% | 177 |
|
|
2024
Q3 | $828K | Buy |
4,193
+130
| +3% | +$24.3K | 0.03% | 168 |
|
|
2024
Q2 | $697K | Sell |
4,063
-22
| -0.5% | -$3.64K | 0.03% | 176 |
|
|
2024
Q1 | $744K | Buy |
4,085
+415
| +11% | +$71.5K | 0.03% | 182 |
|
|
2023
Q4 | $569K | Buy |
3,670
+1,039
| +39% | +$151K | 0.03% | 194 |
|
|
2023
Q3 | $392K | Sell |
2,631
-535
| -17% | -$78.5K | 0.02% | 216 |
|
|
2023
Q2 | $427K | Sell |
3,166
-25
| -0.8% | -$3.67K | 0.02% | 226 |
|
|
2023
Q1 | $509K | Sell |
3,191
-1,799
| -36% | -$275K | 0.03% | 178 |
|
|
2022
Q4 | $807K | Sell |
4,990
-1,305
| -21% | -$200K | 0.06% | 124 |
|
|
2022
Q3 | $845K | Buy |
6,295
+23
| +0.4% | +$3.3K | 0.06% | 113 |
|
|
2022
Q2 | $961K | Buy |
6,272
+90
| +1% | +$13.8K | 0.07% | 100 |
|
|
2022
Q1 | $1M | Buy |
6,182
+986
| +19% | +$143K | 0.06% | 115 |
|
|
2021
Q4 | $704K | Buy |
5,196
+838
| +19% | +$99K | 0.04% | 149 |
|
|
2021
Q3 | $470K | Buy |
4,358
+914
| +27% | +$104K | 0.03% | 165 |
|
|
2021
Q2 | $388K | Buy |
+3,444
| New | +$388K | 0.03% | 138 |
|
|
2020
Q4 | – | Sell |
-1,516
| Closed | -$132K | – | 112 |
|
|
2020
Q3 | $132K | Sell |
1,516
-1,399
| -48% | -$132K | 0.03% | 123 |
|
|
2020
Q2 | $278K | Sell |
2,915
-922
| -24% | -$81.2K | 0.06% | 89 |
|
|
2020
Q1 | $315K | Sell |
3,837
-1,254
| -25% | -$107K | 0.09% | 66 |
|
|
2019
Q4 | $451K | Buy |
5,091
+2,239
| +79% | +$186K | 0.11% | 73 |
|
|
2019
Q3 | $209K | Buy |
+2,852
| New | +$196K | 0.06% | 112 |
|
|
2019
Q2 | – | Sell |
-2,655
| Closed | -$207K | – | 122 |
|
|
2019
Q1 | $207K | Sell |
2,655
-97
| -4% | -$7.93K | 0.07% | 110 |
|
|
2018
Q4 | $220K | Buy |
+2,752
| New | +$242K | 0.1% | 81 |
|
Other funds holding ABBV
Advisory Alpha's ABBV Position: Q2 2026 in Review
Advisory Alpha increased its AbbVie (ABBV) stake by 18% in Q2 2026, buying an estimated $326K and bringing the position to 9,774 shares worth $2.46M. The position accounts for 0.06% of the portfolio, ranked #122.
Advisory Alpha first reported a position in ABBV in Q4 2018 and has held it in 28 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Advisory Alpha held 9,774 shares of AbbVie worth $2.46M as of Q2 2026.
- Advisory Alpha bought 1,514 AbbVie shares in Q2 2026, an estimated $326K.
- AbbVie made up 0.06% of Advisory Alpha's portfolio in Q2 2026, its #122 holding.
- Advisory Alpha first reported a position in AbbVie in Q4 2018 and has held it in 28 quarters since.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Advisory Alpha's 13F filing for Q2 2026, filed 11 Aug 2026.